| 34.06 0.09 (0.26%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 45.68  |
1-year : | 52.84 |
| Resists | First : | 39.11 |
Second : | 45.24 |
| Pivot price | 33.96 |
|||
| Supports | First : | 29.2 | Second : | 24.3 |
| MAs | MA(5) : | 32.02 |
MA(20) : | 34.47 |
| MA(100) : | 32.7 |
MA(250) : | 21.96 |
|
| MACD | MACD : | -1.9 |
Signal : | -1.8 |
| %K %D | K(14,3) : | 45.2 |
D(3) : | 31.4 |
| RSI | RSI(14): 45.8 |
|||
| 52-week | High : | 47.84 | Low : | 3.43 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KOD ] has closed below upper band by 48.9%. Bollinger Bands are 14.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 35.33 - 35.46 | 35.46 - 35.57 |
| Low: | 32.92 - 33.07 | 33.07 - 33.21 |
| Close: | 33.81 - 34.03 | 34.03 - 34.23 |
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Mon, 08 Jun 2026
Kodiak Sciences Inc. - MLQ.ai
Sat, 06 Jun 2026
Kodiak Sciences Zenkuda Trial Win Puts Cash Needs And Growth In Focus - Sahm
Fri, 05 Jun 2026
Kodiak Sciences CFO John Borgeson sold $1.02 million in NASDAQ:KOD shares - Investing.com
Fri, 05 Jun 2026
Kodiak Sciences Inc. (KOD) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow - Seeking Alpha
Fri, 05 Jun 2026
KOD News | KODIAK SCIENCES INC (NASDAQ:KOD) - ChartMill
Thu, 04 Jun 2026
Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 63 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 5.1 (%) |
| Held by Institutions | 99.5 (%) |
| Shares Short | 10,200 (K) |
| Shares Short P.Month | 10,320 (K) |
| EPS | -4.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.8 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -49.1 % |
| Return on Equity (ttm) | -208.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -147 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -8.17 |
| PEG Ratio | 0 |
| Price to Book value | 18.81 |
| Price to Sales | 0 |
| Price to Cash Flow | -14.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|